Redefining Gastrointestinal Oncology in the Precision Era: Immunotherapy Integration and Systemic Disparities

Abstract

Bilal Rahimuddin

Gastrointestinal (GI) malignancies account for a disproportionate share of global cancer mortality and remain among the most biologically complex and therapeutically challenging tumors in clinical oncology. Historically limited by late- stage diagnosis and modest treatment efficacy, the field has recently undergone a fundamental transformation driven by advances in genomic profiling, immunotherapy, perioperative optimization, and real-world outcomes research. This review synthesizes contemporary developments across gastroesophageal, pancreatic, hepatobiliary, and colorectal cancers, emphasizing the growing role of precision oncology, immune checkpoint inhibition, circulating tumor DNA (ctDNA), and population-level insights into health disparities. Integrating data from randomized trials, translational studies, registry analyses, and recent international conference reports, we explore how these innovations are reshaping risk stratification and therapeutic decision-making while simultaneously exposing persistent inequities in access, outcomes, and survivorship. The convergence of biologic innovation with structural reform will be essential to ensure that scientific progress translates into equitable clinical benefit.

PDF